Roche Hldg Ltd Spons (RHHBY) 36.9900 $RHHBY
Genentech's Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer by 15.7 Months Compared to Herceptin and Chemotherapy
Business Wire - Sun Sep 28, 2:01AM CDT
--Median overall survival of almost five years is the longest observed to date in people with this aggressive type of advanced breast cancer
Switzerland's Prescription Drug Tactics Should Make Americans Jealous
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 27, 1:51PM CDT
Source: Flickr user StockMonkeys.com. When it comes to developed countries, no country within the Organisation for Economic Co-operation and Development has higher per-capita health expenditures than the United States. As of 2013 and including...
Roche Announces Positive Results from Studies on Avastin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 12:00PM CDT
Roche (RHHBY) announced positive results from the phase III study, IMELDA, on breast cancer drug Avastin.
3 Reasons Illumina, Inc.'s Stock Could Rise
Alex Planes, The Motley Fool - Motley Fool - Tue Sep 23, 8:40AM CDT
While it's far from a household name, Illumina is often the first word in the red-hot field of genomic sequencing. Illumina has been a strong stock since it went public 14 years ago, rewarding shareholders with lifetime returns of over 750%. ...
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.
Breast Cancer Occurs Most Often in These 5 States
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 21, 8:21AM CDT
Source: Flickr user Paul Falardeau. With the exception of certain types of skin cancers, breast cancer is the most commonly diagnosed cancer in women. Though the disease is by no means relegated just to women -- more than 2,000 cases were...
SmarTrend Watching for Potential Pullback in Shares of Roche Holding After 1.43% Gain
Comtex SmarTrend(R) - Thu Sep 18, 4:21PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $37.79 to a high of $38.00. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $37.65 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
Organovo Holdings Inc Stock: 3 Crucial Pieces of Information Revealed
Brian Stoffel, The Motley Fool - Motley Fool - Thu Sep 18, 9:48AM CDT
Long-term shareholders of Organovo Holdings have been anxiously awaiting the launch of the company's 3-D liver assays—its first real product. But that won't happen until the end of this year—and we won't know how much revenue it produces until...
Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Why ImmunoGen, Inc. Stock Crashed 22% in 2014
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 17, 8:14AM CDT
It's generally been a good year for the overall stock market, but an even better year for the SPDR S&P Biotech ETF , which is up 24% year to date. Given this strong move higher, most investors would be under the impression that biotech stocks...
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 5:10PM CDT
Roche (RHHBY) announced that it has initiated two phase III studies on ophthalmology candidate, lampalizumab.
Why Roche (RHHBY) Stock Is Up Today
at The Street - Tue Sep 16, 2:02PM CDT
CEO Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN) was "exceptional" and not a sign of more ambitious plans for major acquisitions.
IBD 50 Names Hold Gains, But Actionable Charts Scarce
at Investor's Business Daily - Mon Sep 15, 1:37PM CDT
Plenty of IBD 50 names are showing resilience and holding near highs. Damaged charts are the exception, not the rule. That's the good news. The bad news is that new buys aren't easy to find for growth investors looking to put new money to work. A...
Why Exelixis Inc. Stock Crashed By 70% in 2014
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 13, 9:00AM CDT
The benchmark S&P 500 may have crossed the psychological 2,000 point mark, and the Dow Jones Industrial Average have crested 17,000, but it's been an abysmal year if you're a shareholder in Exelixis , like I am. EXEL data by ...
EVSV, RHHBY, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Fri Sep 12, 9:13AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. ENVIROSERVE INC (OTC:EVSV), Roche Holding AG (OTC:RHHBY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014
Sean Williams, The Motley Fool - Motley Fool - Fri Sep 12, 9:10AM CDT
The biotech sector, perhaps more than any other sector, is a breeding ground for large stock moves. This is because biotech stocks are predominantly valued based on their future sales potential as well as Wall Street forecasts for how many people...
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:40PM CDT
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Genentech's Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer by 15.7 Months Compared to Herceptin and Chemotherapy
Business Wire - Sun Sep 28, 2:01AM CDT
--Median overall survival of almost five years is the longest observed to date in people with this aggressive type of advanced breast cancer
Switzerland's Prescription Drug Tactics Should Make Americans Jealous
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 27, 1:51PM CDT
Source: Flickr user StockMonkeys.com. When it comes to developed countries, no country within the Organisation for Economic Co-operation and Development has higher per-capita health expenditures than the United States. As of 2013 and including...
Roche Announces Positive Results from Studies on Avastin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 12:00PM CDT
Roche (RHHBY) announced positive results from the phase III study, IMELDA, on breast cancer drug Avastin.
3 Reasons Illumina, Inc.'s Stock Could Rise
Alex Planes, The Motley Fool - Motley Fool - Tue Sep 23, 8:40AM CDT
While it's far from a household name, Illumina is often the first word in the red-hot field of genomic sequencing. Illumina has been a strong stock since it went public 14 years ago, rewarding shareholders with lifetime returns of over 750%. ...
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.
Breast Cancer Occurs Most Often in These 5 States
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 21, 8:21AM CDT
Source: Flickr user Paul Falardeau. With the exception of certain types of skin cancers, breast cancer is the most commonly diagnosed cancer in women. Though the disease is by no means relegated just to women -- more than 2,000 cases were...
SmarTrend Watching for Potential Pullback in Shares of Roche Holding After 1.43% Gain
Comtex SmarTrend(R) - Thu Sep 18, 4:21PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $37.79 to a high of $38.00. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $37.65 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
Organovo Holdings Inc Stock: 3 Crucial Pieces of Information Revealed
Brian Stoffel, The Motley Fool - Motley Fool - Thu Sep 18, 9:48AM CDT
Long-term shareholders of Organovo Holdings have been anxiously awaiting the launch of the company's 3-D liver assays—its first real product. But that won't happen until the end of this year—and we won't know how much revenue it produces until...
Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Why ImmunoGen, Inc. Stock Crashed 22% in 2014
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 17, 8:14AM CDT
It's generally been a good year for the overall stock market, but an even better year for the SPDR S&P Biotech ETF , which is up 24% year to date. Given this strong move higher, most investors would be under the impression that biotech stocks...
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 5:10PM CDT
Roche (RHHBY) announced that it has initiated two phase III studies on ophthalmology candidate, lampalizumab.
Why Roche (RHHBY) Stock Is Up Today
at The Street - Tue Sep 16, 2:02PM CDT
CEO Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN) was "exceptional" and not a sign of more ambitious plans for major acquisitions.
IBD 50 Names Hold Gains, But Actionable Charts Scarce
at Investor's Business Daily - Mon Sep 15, 1:37PM CDT
Plenty of IBD 50 names are showing resilience and holding near highs. Damaged charts are the exception, not the rule. That's the good news. The bad news is that new buys aren't easy to find for growth investors looking to put new money to work. A...
Why Exelixis Inc. Stock Crashed By 70% in 2014
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 13, 9:00AM CDT
The benchmark S&P 500 may have crossed the psychological 2,000 point mark, and the Dow Jones Industrial Average have crested 17,000, but it's been an abysmal year if you're a shareholder in Exelixis , like I am. EXEL data by ...
EVSV, RHHBY, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Fri Sep 12, 9:13AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. ENVIROSERVE INC (OTC:EVSV), Roche Holding AG (OTC:RHHBY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014
Sean Williams, The Motley Fool - Motley Fool - Fri Sep 12, 9:10AM CDT
The biotech sector, perhaps more than any other sector, is a breeding ground for large stock moves. This is because biotech stocks are predominantly valued based on their future sales potential as well as Wall Street forecasts for how many people...
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:40PM CDT
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
